These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16448327)

  • 21. [Insulin detemir (Levemir)].
    Scheen AJ; Radermecker RP; Philips JC; Paquot N
    Rev Med Liege; 2005 Oct; 60(10):814-9. PubMed ID: 16358671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH; Nattrass M; Pieber TR
    Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K; Davies M
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Insulin analogues: place of detemir (levemir)].
    Dorchy H; Sternon J
    Rev Med Brux; 2006; 27(2):89-94. PubMed ID: 16736846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can we reduce hypoglycaemia with insulin detemir?
    Mathieu C
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S35-40. PubMed ID: 15306836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.
    Raslová K; Tamer SC; Clauson P; Karl D
    Clin Drug Investig; 2007; 27(4):279-85. PubMed ID: 17358100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
    Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin detemir: A historical perspective on a modern basal insulin analogue.
    Meneghini L; Liebl A; Abrahamson MJ
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S31-42. PubMed ID: 20394890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.
    Chatterjee S; Tringham JR; Davies MJ
    Expert Opin Pharmacother; 2006 Jul; 7(10):1357-71. PubMed ID: 16805721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L; Koenen C; Weng W; Selam JL
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin detemir in the treatment of type 1 and type 2 diabetes.
    Philips JC; Scheen A
    Vasc Health Risk Manag; 2006; 2(3):277-83. PubMed ID: 17326333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of insulin detemir.
    Raskin P
    Endocrinol Metab Clin North Am; 2007 Aug; 36 Suppl 1():21-32. PubMed ID: 17881329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.